Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MicroCor hPTH(1-34) transdermal system versus Forteo in healthy postmenopausal women
ACTRN12615000195550Phase 2Completed
- Sponsor
- Corium
- Start
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MicroCor hPTH(1-34) and teriparatide in osteoporosis (3 arms), sponsored by Corium. Primary endpoint: Primary pharmacokinetic variables. Started Feb 2015; status: completed.
02
Drugs
MicroCor hPTH(1-34)teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12615000195550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000195550.